SELLAS Presents SLS009 Preclinical Data in Pancreatic Cancer
NEW YORK — September 25, 2026 SELLAS Life Sciences Group presented new preclinical data for SLS009 (tambiciclib) in patient-derived...
PDAC
Advertisement
Kestrel Therapeutics Gains FDA Fast Track for KST-6051
WATERTOWN, Mass. — September 15, 2026 Kestrel Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Revolution Medicines Gains FDA Breakthrough Designation for RASONQUE
REDWOOD CITY, Calif. — September 14, 2026 Revolution Medicines, Inc. announced that the U.S. Food and Drug Administration (FDA)...
Verastem Oncology Advances VS-7375 Across KRAS G12D Cancers
BOSTON, Massachusetts — September 8, 2026 Verastem Oncology announced plans to host an investor event and webcast on October...
SELLAS Presents SLS009 Preclinical Data in Pancreatic Cancer at AACR 2026
New York, September 2, 2026 SELLAS Life Sciences Group, Inc. announced that three abstracts evaluating SLS009 (tambiciclib), a potent...
Advertisements
Propanc Advances PRP After Strong Preclinical Pancreatic Cancer Results
Melbourne, Australia – August 27, 2026 Propanc Biopharma announced new preclinical and early translational data for PRP in pancreatic...
Caris Life Sciences Links AI to Longer Survival in Pancreatic Cancer
Irving, Texas, United States, Aug 27, 2026 Caris Life Sciences has announced the publication of a study in npj...
Revolution Medicines Wins FDA Approval for RASONQUE™ in Metastatic Pancreatic Cancer
REDWOOD CITY, Calif., August 26, 2026 Revolution Medicines, Inc. has received U.S. Food and Drug Administration (FDA) approval for...
IDEAYA and Genentech Advance KRAS G12D Cancer Trial
South San Francisco, California, August 19, 2026 IDEAYA Biosciences has entered into a clinical collaboration with Genentech, a member...
Phanes Therapeutics Gains FDA Fast Track for Spevatamig
San Diego, California, August 14, 2026 Phanes Therapeutics, Inc., a clinical-stage biotechnology company focused on immuno-oncology drug discovery and...
Advertisement
